The treatment of reflux oesophagitis by histamine H2-receptor blockers is unsatisfactory because approximately 50% of patients remain not only symptomatic, but also unhealed endoscopically after six to eight weeks' treatment. ' Omeprazole, a powerful proton pump inhibitor, has been shown to be more effective than ranitidine" and placebo7 in the short term treatment of reflux oesophagitis and in the treatment of reflux oesophagitis resistant to longterm high dose cimetidine therapy. 8 No study has compared the efficacy and rates of healing of oesophagitis in patients receiving omeprazole and the recommended dose of cimetidine. In addition, the present study has assessed therapy not only by symptom scoring and endoscopy, but also by histology and 24 h ambulatory pH measurements.
Methods

PATIENTS
Sixty seven outpatients, aged between 18 and 80 years, with symptomatic, gastro-oesophageal reflux, confirmed both endoscopically and histologically, were randomised to receive eight weeks of continuous treatment with omeprazole 40 mg once daily or cimetidine 400 mg four times daily using a double blind, double dummy technique. STUDY 
PROTOCOL
Oesophagitis was graded endoscopically as grade I (erythema), grade II (isolated round and linear erosions incompletely involving the lower 2 cm of oesophagus), grade III (erosions above 2 cm or involving the entire circumference), grade IV (benign ulcer), and grade V (stricture). Oesophageal biopsies were also graded: grade I (basal cell hyperplasia without inflammatory infiltration), grade II (I plus extension of papillae and mild inflammatory infiltration), grade III (massive polymorpho-nuclear infiltration), grade IV (III plus ulceration). Grade Table I illustrates the pre-entry characteristics of these patients: 31 were randomised to receive omeprazole and 36 cimetidine. During the course of the study two patients (one omeprazole; one cimetidine) were withdrawn for protocol violations, one patient (cimetidine) for lack of compliance, and three patients (one omeprazole; two cimetidine) for adverse events (vomiting, secondary to development of oesophageal stricture; diarrhoea; malaise and lethargy): thus the per protocol analysis at four weeks included 28 patients on omeprazole and 31 patients on cimetidine.
All patients had one or more symptoms of heartburn, regurgitation, or dysphagia. Table II illustrates the severity score for heartburn. After two weeks' treatment with omeprazole, heartburn was completely relieved in 18/25 (72%) compared with 12/30 (40%) patients on cimetidine (p=0-0061) in whom this symptom was noted at presentation. After four weeks, heartburn was relieved in 23/25 (92%) and 16/30 (53%; p=0 001) of patients respectively and remained substantially unchanged at the eight week assessment. There was no significant difference between treatments in the relief of symptoms of either regurgitation of dysphagia. Table II also illustrates the pre-entry occurrence of symptomatic regurgitation and dysphagia. At the four week assessment, regurgitation was present in three of 28 (11%) of patients on omeprazole and nine of 31 (29%) on cimetidine (p=0 09): dysphagia was present in four of 28 (14%) and six of 31 (19%; p>0 2).
Between days 0-15 the median number (± 1/2 interquartile range) of diary card reports of daytime reflux symptoms were 0-21 (0 14) (omeprazole) and 0-38 (0 37) (cimetidine; p= NS). After four weeks of treatment there was a significant reduction between treatment groups in the diary card record of daytime reflux symptoms to 0 0 (0 12) (omeprazole) and 0-32 (0 27) (cimetidine) (p=0004): night time relux symptoms were also significantly reduced in omeprazole patients but not in the cimetidine group. Between days 0-15 median daily antacid tablet consumption was 0 23 (0 23) (omeprazole) and 0-65 (0 55) (cimetidine; p=NS): between days 16-29 median daily consumption fell to 0 0 (0-14) (omeprazole) and 0 48 (0 45) (cimetidine) (p=00005). The differences between treatment groups were sustained through the remaining four weeks of therapy. Figure 2 illustrates the endoscopic grading of oesophagitis before entry, and after four and eight weeks therapy. After four weeks' treatment with omeprazole and cimetidine, healing (complete re-epithelialisation) had occurred in 16/28 (57%) and nine of 31 (29%) respectively (p= Figure 3 . There were no significant differences in the recorded pH parameters at the pre-entry tests. Both total and daytime oesophageal acid exposure were significantly less at four weeks in the omeprazole treated patients. There was no significant difference between treatments in night time oesophageal acid exposure after four weeks, although all but two of the omeprazole treated patients recorded a decrease in nocturnal acid exposure (Fig 3) .
Both day and night time oesophageal acid exposure was abolished in the six patients on omeprazole in whom endoscopic oesophagitis had healed. In those five patients with endocopic healing after four weeks' cimetidine treatment, a daytime acid (pH<4) exposure in excess of 5% was recorded in three and night time exposure in excess of 2% persisted in two patients.
In the three endoscopically unhealed patients receiving omeprazole, mean daytime oesophageal acid exposure fell from 20 7 to 2 1%, but remained >5% in only one patient. Mean night time acid exposure did not change (19A4% v 21 3%), remaining above 2% in all three patients and being reduced in only one patient. In the four endoscopically unhealed patients receiving cimetidine, daytime oesophageal acid exposure increased in three patients and night time exposure increased in three of the four patients. There was no consistent relationship between endoscopic grading at pre-entry with recorded acid exposure.
Haematological and biochemical results remained within normal ranges throughout the study period. Gastrin serum concentrations were measured at entry (median (range): omeprazole: 5 (3-20) pmol/l: cimetidine: 8 (3-35) pmol/l) and after four (omeprazole: 9 (2-51) pmol/l: cimetidine: 10 (4-19) pmolJl) and eight (omeprazole: 11 (5-17) pmol/l: cimetidine: 7 (4-19) pmol/l) weeks of treatment, were well with the normal range (omeprazole 2-51 pmol/l; cimetidine 3-35 pmol/l) and there was no significant difference between treatment groups.
Discussion
The patients in our study were well matched before entry, in all aspects of their oesophageal reflux disease although slightly more patients in the cimetidine group had previous gastrointestinal complications and had received previous medical therapy. The We defined endoscopic healing of oesophagitis as complete circumferential re-epithelialisation. Endoscopic healing rates of oesophagitis in patients treated with omeprazole for four weeks have been reported to vary between 76% and 85%,46 although two reports46 included the presence of endoscopic erythema as evidence of healing and Vantrappen' defined healing as the disappearance of oesophageal ulceration. The latter definitions and the higher dose of omeprazole (60 mg) used by Klinkenberg-Knol4 would explain the difference in endoscopic healing rates reported between this and the other studies. Further advantages of omeprazole therapy are shown by the fact that, during the period of the present study, no patient receiving omeprazole had worsening of the grade of endoscopic oesophagitis and, moreover, the endoscopic grading remained unchanged in only two patients. In contrast, of the 31 patients receiving cimetidine, the endoscopic grading worsened in five and remained unchanged in five.
Havelund et all and Whitehead et al9 have shown respectively that histological grading of oesophagitis is improved to a greater extent with omeprazole therapy compared with ranitidine and placebo. Our study confirms these findings but also has demonstrated that after eight weeks of therapy histological gradings are similar in the two therapeutic groups. This implies that administration of both drugs produces histological healing of oesophagitis, but omeprazole, at 40 mg daily, achieves healing more rapidly.
A major factor in the cause of a reflux oesophagitis is inappropriate exposure of the distal oesophagus to gastric acid.'0 Oesophageal pH monitoring provides a useful indicator of the degree and pattern of this acid exposure" although caution must be used in interpreting the results because of variation within individuals.'2 In order to minimise the variability of this investigation the methods that we used for -performing repeated recordings of oesophageal pH were as standardised as possible. The results of the 24 h oesophageal pH measurement show that omeprazole is far more effective in increasing the pH of gastro-oesophageal refluxate by comparison to cimetidine. Moreover, omeprazole treatment completely abolished acid reflux in six of the nine patients receiving that drug who underwent pH recordings.
In those patients in whom endoscopic healing was recorded omeprazole reduced oesophageal acid exposure to a much greater degree than cimetidine (Table III) .
Nocturnal acid reflux, because of its prolonged contact with and poor clearance'3 from the distal oesophagus is believed to be extremely injurious to the oesophageal epithelium.8 14 This view is supported by the fact that in three of the four patients receiving cimetidine, and without endoscopic healing, nocturnal acid exposure increased substantially. In only one of three patients receiving omeprazole, and in whom endoscopic oesophagitis persisted, did nocturnal 
